Aims: Using the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c.
| INTRODUC TI ON
Nowadays, real-time continuous glucose monitoring (CGM) is increasingly used for diabetes management. 3
Few major problems though still hamper the use of CGM for glucose management on a large scale, that is, the need of daily finger-stick BGM for device calibration, the short sensor lifetime and the price. 4 An alternative technology, the FreeStyle Libre (FSL) glucose monitoring (FGM), recently made available by Abbott Diabetes Care, overcome these pitfalls. 4 FSL continuously measures interstitial fluid glucose levels in real time. In contrast to CGM systems, FGM is based on the use of low cost, factorycalibrated 14-day small size patch glucose sensors with MARD close to 10%. [5] [6] [7] Interstitial fluid glucose levels are measured [AGP]) that generates standardized glucose summaries stored as PDF files. [8] [9] [10] As they provide reliable information about glucose control and variability, incidence, depth and duration of hypoglycaemic events, AGP-generated graphs can be easily used by the patient, either alone or with health care professionals (HCP) as an educational tool.
"Real-world" data looking at more than 400 million individual glucose measurements recently reported that the best HbA1c values and time in range (between 70 mg/dL and 180 ml/dL) were observed among users performing the highest number of scans per day.
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These data are in accordance with those previously reported in the IMPACT trial which showed in 328 well-controlled individuals with type 1 diabetes that the time spent in nocturnal hypoglycaemia and the number of serious hypoglycaemia (<55 mg/dL) were significantly reduced among individuals wearing the device. These results came along significant improvement in parameters of quality of live. 12 Similar results were found in individuals with type 2 diabetes in the REPLACE program which also showed that time spent in hypoglycaemia was significantly reduced after 6 and 12 months along with improvement in treatment satisfaction. 13, 14 In this study, we sought of analysing FGM-induced effects on the glycaemic control (HbA1c and hypoglycaemic events) in a cohort of individuals with type 1 diabetes followed in real-live conditions as those occurring in the daily clinical practice in an outpatient diabetes clinic. clinical trial, there were no specific exclusion criteria, except the current use of another CGM system, the nonacceptance of this new method of glucose monitoring, a greatly altered medical condition, the nonadherence to the clinic visit every 3 months, the inability of using the FGM system, the known allergy to medical-grade adhesives, and pregnancy. The study was performed according a protocol approved by the local Ethic Review Committee.
| S TUDY DE S I G N AND PARTI CIPANTS
Baseline diabetes and anthropometric characteristics were recorded from each participant using standardized records. Each of them was then individually trained on how to set the device up on the back of the upper arm every 2 weeks. The device was immediately unblinded allowing patients to readily visualize glucose values. During the next 2 weeks, participants did not receive specific instructions for insulin dose self-management. They were though asked to keep recording glucose levels in a diary and to take appropriate measures as they were previously trained to do when using finger sticks. After 2 weeks, they were seen again to check for technical pitfalls and to make sure they correctly understood how to use the device and to set a new sensor up. Their glucose data were then uploaded from the reader and AGP-derived reports were generated.
The data were thoroughly reviewed together with HCP who provided insulin titration algorithms to tightly adapt insulin dosages regarding glucose levels. Instructions were given to anticipate as much as possible hypoglycaemic episodes, to optimize fasting glucose levels and to reduce postprandial glucose excursions. Participants were invited to scan the sensor as many times as they believe to be necessary for glucose self-management and insulin dose adaptations. Each of them was then seen every 3 months over a period of 1 year for weight measurement, insulin dosage recordings, sensor data uploading and diabetes education.
For the statistical analysis, 3 groups of individuals were considered; the entire cohort, the subgroup of them with HbA1c ≥ 7.5%
at baseline (more than 2-thirds of the cohort) and the subgroup of them with HbA1c < 7.5% at baseline. This splitting was performed to identify which individual with type 1 diabetes is taking the most benefit from the FGM system. 
| RE SULTS

| Patient characteristics at baseline
Out Table 1A ).
The average number of glucose controls per day by BGM before receiving the first sensor (T0-15d) was 2.88 ± 0.12/d. As soon as participants had access to FGM and received the green light for insulin dose adjustment (T0: 2 weeks after having received the first sensor), they stopped nearly immediately of checking capillary blood glucose levels by BGM. By contrast, the number of sensor scans per day significantly raised up to 8.87 ± 0.58/d and remained stable throughout the study period (8.85 ± 0.69/d at T12) (Table 1B) .
There was a slight increase in BMI values which reached the statistical significance only at T6 (26.69 ± 0.62 kg/m 2 ) as compared to T0 (25.93 ± 0.51 kg/m 2 ) (P < .05). This moderate weight gain was observed only in individuals with baseline HbA1c levels ≥7.5% (Table 2) .
| The HbA1c levels significantly decrease in individuals with type 1 diabetes using FGM
When the whole cohort of participants was taken into consideration, there was a significant reduction in HbA1c levels with a decrease from 8.51% ± 0.14% to 7.77% ± 0.95% already at visit T3 compared to T0 (P < .0001). This value flattened at 6 months to slightly (but significantly) increase up to 7.91% ± 1.11% and 7.92% ± 0.09%
at T9 and T12, respectively ( Figure 1A ). The decrease in HbA1c levels was driven by the subgroup of individuals with baseline HbA1c ≥ 7.5%. Among those participants, HbA1c levels dropped from 8.95% ± 0.14% to 8.03% ± 0.09%, 7.99% ± 0.1%, 8.2% ± 0.13% and 8.16% ± 0.09% at T3, T6, T9 and T12 (P < .0001), respectively ( Figure 1B ). By contrast, there was no change in HbA1c levels in the subgroup of participants with baseline HbA1c < 7.5%. There was even a progressive increase in HbA1c levels which reached the significance at T12 (7.14% ± 0.16%) as compared to T0 (6.8% ± 0.11%; P < .05; Figure 1C ).
As shown in Figure 2 , there was a negative correlation between the number of scans per day and the decrease in HbA1c levels. This negative correlation was observed at all time-points and in the 2 subgroups of patients regardless baseline HbA1c levels.
| The number, but not the duration, of hypoglycaemic events increases in individuals with type 1 diabetes using FGM
There has been no episode of severe hypoglycaemia (requiring thirdparty assistance and/or injection of glucagon) during the entire period of observation.
When considering the whole cohort of participants, the number of hypoglycaemic events (defined as glucose levels < 70 mg/dL [3.9 mmol/L]) significantly increased from 16.9 ± 1.44 events/month to 22.9 ± 2.03 events/month at T3 (P < .001). The TA B L E 1 (A) Characteristics of participants at baseline. A total of 120 individuals with type 1 diabetes were included in this observational prospective study. TA B L E 2 BMI (body mass index) and insulin dosages number of hypoglycaemic episodes at T6, T9 and T12 was alike to T3, but again significantly increased compared to T0 (P < .05) ( Figure 3A) . The increased number of mild hypoglycaemic events was mostly observed in the subgroup of participants with baseline HbA1c levels ≥7.5% ( Figure 3B ). This increase was transient with a peak at T6 (26.2 ± 2.7 events/month) compared to T0 (17 ± 1.6 events/month) which then decreased at T12 (20.38 ± 2.06 events/ month). A positive trend was also observed in the subgroup of participants with baseline HbA1c levels <7.5%, but, compared to T0 (16.4 ± 3.7 events/month), the statistical significance was observed only at T3 (28.5 ± 5.6 events/month) and not at the other time-points, likely because of the lower number of individuals in this subgroup ( Figure 3C ).
When the whole cohort was taken into consideration, there were no frank changes in the duration of hypoglycaemic events. It slightly decreased at T3 as compared to T0, but only in the subgroup of participants with baseline HbA1c levels ≥7.5% ( Figure 3D-F) .
As expected and reported in Figure S1 , there was a negative correlation between the number of hypoglycaemic events and HbA1c levels.
| The total daily insulin dose (TDD) remained stable over time with changes in the long-acting/ rapid-acting insulin ratio
Insulin TDD was higher in participants with baseline HbA1c levels ≥7.5% (0.74 ± 0.03 U/kg/d) compared to those with baseline HbA1c levels <7.5% (0.62 ± 0.03 U/kg/d). TDD remained stable over time, with a transient decrease that was significant at T3
in the entire cohort and in the subgroup of participants with baseline HbA1c levels ≥7.5%. As shown in Table 2 
| D ISCUSS I ON
In accordance with previous studies, [4] [5] [6] [7] [11] [12] [13] [14] our data confirm that the FGM system is easy to use and quite convenient for people with The main finding of the study was the significant decrease in Regarding the subgroup of well-controlled participants with baseline HbA1c levels <7.5%, our results are partly in accordance with those reported by Bolinder et al. 12 In this randomized controlled study, therefore different from the observational design of our study, there was a 38% reduction in the time spent in hypoglycaemia at night and a 50% reduction in serious hypoglycaemia in the intervention group. HbA1c levels were unchanged after 6 months. In contrast with our study, the intervention group in the Bolinder study was exclusively composed of highly motivated and well-empowered individuals who were deeply involved in daily diabetes self-management. Noteworthy, although participants in the intervention group had direct access to the glucose data, and again in contrast with our study, no specific instruction was given for them to interpret these data. In our study, the education strategy was different as participants, as soon as 2 weeks after having received the first sensor, were strongly encouraged of using glucose data displayed by the reader to modify insulin dosages according to treatment algorithms provided by HCPs. Compared to less-controlled participants, the glycaemic control did not further improve among those well-controlled at baseline. HbA1c levels even moderately increased by the end of the observation period, but at a level (7.14%)
that can be still considered as acceptable regarding the international recommendations. In the meantime, there was a positive trend in the number of mild hypoglycaemia which can be explained by the fact that although the amount of long-acting insulin was reduced, the amount of rapid-acting insulin increased overtime when measured in the cohort taken as a whole. After questioning participants, it appeared that, because of their increased confidence in the FGM technology, they were inclined of taking more audacious therapeutic decisions to challenge for instance postprandial glucose excursions.
There was in general less fear of hypoglycaemic events because of the participant's ability to quickly recognize and correct them and to better anticipate events thanks to the glucose trends arrows that were considered, beside displayed actual glucose levels, as the most The improvement in HbA1c values observed in our study is also in agreement with recent papers that reported improved glycaemic control in people with type 1 and type 2 diabetes who are using CGM systems on a regular basis.
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There was a clear and significant correlation between the number of scans per day and improved HbA1c levels, again in accordance with previous studies, for instance the real-world data which showed a significant decrease in HbA1c levels among individuals who checked daily glucose levels at the highest rate. In summary, our data indicate that the FGM system used in dayto-day clinical practice is a well-tolerated technology that is readily adopted by the vast majority of people with type 1 diabetes. Beyond the unquestionable comfort this new technology offers, it improves per se the glycaemic control in people with type 1 diabetes followed in real-life conditions. This new technology provides real-time reliable glucose information and glucose trends that are proactively used by people with type 1 diabetes for fine-tuning therapeutic decision and adaptation of insulin dosages. This beneficial effect is obtained in a context of structured therapeutic education and is correlated with the number of scans per day. As long as the motivation is kept intact, the FGM technology contributes to empower people with type 1 diabetes. It reinforces their confidence in the ability to better improve the glycaemic profile, while foreseeing possible hypoglycaemic events that can be then anticipated or at least better controlled.
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